Your browser is no longer supported. Please, upgrade your browser.
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own1.20% Shs Outstand105.40M Perf Week1.76%
Market Cap608.16M Forward P/E- EPS next Y-0.96 Insider Trans-3.22% Shs Float97.46M Perf Month-1.70%
Income-77.30M PEG- EPS next Q-0.24 Inst Own91.50% Short Float10.49% Perf Quarter10.75%
Sales19.70M P/S30.87 EPS this Y-4.10% Inst Trans-1.04% Short Ratio13.06 Perf Half Y15.17%
Book/sh0.63 P/B9.16 EPS next Y1.00% ROA-48.40% Target Price7.83 Perf Year-2.86%
Cash/sh0.87 P/C6.66 EPS next 5Y19.90% ROE-114.40% 52W Range3.95 - 6.67 Perf YTD17.52%
Dividend- P/FCF- EPS past 5Y0.30% ROI-41.50% 52W High-19.64% Beta2.64
Dividend %- Quick Ratio1.40 Sales past 5Y-0.90% Gross Margin94.20% 52W Low35.70% ATR0.28
Employees85 Current Ratio1.40 Sales Q/Q-57.40% Oper. Margin- RSI (14)40.33 Volatility4.41% 4.93%
OptionableYes Debt/Eq0.86 EPS Q/Q-38.20% Profit Margin- Rel Volume0.86 Prev Close5.77
ShortableYes LT Debt/Eq0.29 EarningsMay 08 BMO Payout- Avg Volume782.86K Price5.36
Recom2.40 SMA20-10.89% SMA50-4.15% SMA2003.79% Volume335,674 Change-7.11%
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Sep-09-15Initiated Jefferies Hold
Jun-30-15Upgrade BofA/Merrill Neutral → Buy $12 → $19
Apr-21-15Initiated FBR Capital Outperform $18
Jun-20-18 04:20PM  Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Jun-13-18 10:28AM  Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks
07:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-18 07:30AM  BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera Business Wire
May-29-18 08:00AM  BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress GlobeNewswire
May-24-18 12:30PM  BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema GlobeNewswire
06:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-17-18 09:00AM  Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE
May-14-18 09:51AM  Edited Transcript of BCRX earnings conference call or presentation 8-May-18 3:00pm GMT Thomson Reuters StreetEvents +9.27%
May-10-18 07:05AM  Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient ACCESSWIRE
May-08-18 10:11AM  Will BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Grow In The Years Ahead? Simply Wall St. -9.53%
09:37AM  BioCryst: 1Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:24AM  BioCryst lands European approval for flu treatment American City Business Journals +5.94%
May-01-18 06:00AM  BioCryst Receives European Medicines Agency Approval for ALPIVAB for the Treatment of Influenza GlobeNewswire
Apr-26-18 08:20AM  New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:00AM  BioCryst to Announce First Quarter 2018 Financial Results on May 8 GlobeNewswire
Apr-10-18 02:51PM  Vote on proposed merger of biopharm firms pushed back American City Business Journals
07:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger Business Wire
Apr-03-18 02:38PM  Why another BioCryst shareholder plans to vote against Idera merger American City Business Journals +5.86%
Apr-02-18 08:13AM  RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals PR Newswire
08:00AM  BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals Business Wire
Mar-29-18 05:21AM  Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT Thomson Reuters StreetEvents
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-23-18 11:00PM  Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX) GlobeNewswire
Mar-22-18 12:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-20-18 02:58PM  15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com
Mar-15-18 06:00AM  BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Mar-09-18 07:50AM  Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid ACCESSWIRE
Feb-28-18 06:00AM  BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Feb-27-18 09:35AM  Does BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Growth Make It An Outperformer? Simply Wall St.
09:31AM  BioCryst reports 4Q loss Associated Press
08:30AM  BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
08:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-26-18 08:45AM  BioCryst, Idera outline specifics on merger value American City Business Journals
08:30AM  Options Traders Expect Huge Moves in BioCryst (BCRX) Stock Zacks
Feb-20-18 06:00AM  BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27 GlobeNewswire
Feb-19-18 01:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Feb-16-18 01:20PM  Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Feb-05-18 08:39AM  Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
Jan-23-18 09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
06:35AM  Cambridge's Idera plans eventual move out of state after merger with BioCryst American City Business Journals
Jan-22-18 04:05PM  BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love Motley Fool
03:53PM  SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX PR Newswire
02:20PM  Durham's BioCryst merging with Idera, moving some ops out of state American City Business Journals
08:41AM  BioCryst and Idera to merge into rare disease company MarketWatch
08:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases GlobeNewswire
08:20AM  Todays Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals ACCESSWIRE
Jan-05-18 06:00AM  BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva GlobeNewswire
Jan-03-18 07:00AM  BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.99%
Jan-02-18 02:02PM  Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today Motley Fool +10.79%
Dec-26-17 11:16AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-20-17 08:10AM  Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & Machine, Mercury General, and IQVIA Holdings Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-11-17 08:20AM  Todays Research Reports on Trending Tickers: BioCryst Pharmaceuticals and 22nd Century Group ACCESSWIRE
07:23AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 11, 2017 Capital Cube
Dec-07-17 01:01PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 7, 2017 Capital Cube
Dec-05-17 08:57AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube
Dec-04-17 11:16AM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : December 4, 2017 Capital Cube
Dec-01-17 07:12AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 1, 2017 Capital Cube
Nov-16-17 06:00AM  BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-17 02:12PM  Edited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 10:53AM  Does BioCryst Pharmaceuticals Incs (BCRX) Debt Level Pose A Serious Problem? Simply Wall St.
06:13AM  BioCryst reports 3Q loss Associated Press
06:00AM  BioCryst Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
Nov-02-17 11:52AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 2, 2017 Capital Cube
Nov-01-17 06:00AM  BioCryst to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-27-17 06:00AM  BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAIs 2017 Annual Scientific Meeting GlobeNewswire +6.25%
Oct-24-17 06:00AM  BioCryst to Announce Third Quarter 2017 Financial Results on November 7 GlobeNewswire
Oct-23-17 08:31AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 23, 2017 Capital Cube -8.96%
Oct-17-17 09:35AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017 Capital Cube
Oct-04-17 06:00AM  BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017 GlobeNewswire
Oct-03-17 10:54AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 3, 2017 Capital Cube
Sep-22-17 11:03AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals ACCESSWIRE
Sep-21-17 02:35PM  BioCryst scores FDA approval on flu treatment for children American City Business Journals
12:17PM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 Capital Cube
10:10AM  FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers TheStreet.com
09:55AM  Can BioCryst Turn Itself Around With This FDA Approval? 24/7 Wall St.
09:03AM  Have Investors Already Priced In BioCryst Pharmaceuticals Incs (BCRX) Growth? Simply Wall St.
06:00AM  BioCrysts RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication GlobeNewswire
Sep-15-17 12:00PM  BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
08:00AM  BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB ACCESSWIRE
Sep-14-17 03:15PM  How BioCryst aims to use its $80M public offering American City Business Journals
Sep-12-17 09:00PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -9.04%
10:50AM  BioCryst Pharmaceuticals Announces Secondary Offering 24/7 Wall St.
Sep-11-17 04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
Sep-05-17 10:35AM  BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win 24/7 Wall St.
06:00AM  BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE GlobeNewswire
Sep-04-17 02:00PM  BioCryst Announces Corporate Update Conference Call and Webcast GlobeNewswire
Sep-01-17 09:00AM  Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
Aug-23-17 06:00AM  BioCryst to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-12-17 09:00AM  Edited Transcript of BCRX earnings conference call or presentation 7-Aug-17 3:00pm GMT Thomson Reuters StreetEvents
Aug-07-17 11:57PM  BioCryst reports 2Q loss Associated Press -13.33%
06:00AM  BioCryst Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-02-17 06:00AM  BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks GlobeNewswire
Aug-01-17 05:48PM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : August 1, 2017 Capital Cube
Jul-24-17 02:21PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
06:00AM  BioCryst to Announce Second Quarter 2017 Financial Results on August 7 GlobeNewswire
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sheridan William PSenior VP - CMOJun 01Option Exercise2.5842,112108,64963,170Jun 05 03:07 PM
Sheridan William PSenior VP - CMOJun 01Sale6.3042,112265,30621,058Jun 05 03:07 PM
Stonehouse Jon PPresident & CEOMay 17Option Exercise1.4270,427100,006725,519May 21 09:31 AM
Barnes Alane PVP, General Counsel & Corp SecMay 15Option Exercise1.4212,50017,75098,268May 17 09:25 AM
Babu Yarlagadda SSenior VP - Drug DiscoveryMar 06Option Exercise3.2630,00097,800120,618Mar 08 03:48 PM
Stonehouse Jon PPresident & CEOFeb 28Option Exercise3.2656,949185,654698,316Mar 02 02:23 PM
Barnes Alane PVP, General Counsel & Corp SecFeb 28Option Exercise3.266,70921,87185,768Mar 02 02:21 PM
Sheridan William PSenior VP - CMONov 13Sale4.7264,310303,54323,855Nov 15 04:09 PM
Cohen Fred EDirectorSep 18Option Exercise4.2754,250231,648173,660Sep 20 10:07 AM
Cohen Fred EDirectorSep 18Sale5.4254,250294,035119,410Sep 20 10:07 AM